^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    iC9.GD2.CAR.IL-15 T-cells

    i
    Associations
    News

    Trials

    Company:
    UNC Lineberger Comprehensive Cancer Center
    Drug class:
    IL-15R stimulant, GD2-targeted CAR-T immunotherapy
    Related drugs:
    Associations
    News

    Trials

    Apply
    Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma (NCT03721068)
    Phase 1
    UNC Lineberger Comprehensive Cancer Center
    Recruiting
    Last update posted :
    04/23/2024
    Initiation :
    02/19/2019
    Primary completion :
    06/19/2024
    Completion :
    06/19/2039
    IL15
    |
    cyclophosphamide • fludarabine IV • iC9.GD2.CAR.IL-15 T-cells